Oral Salbutamol

ID: salbutamol_oral

Aliases: oral albuterol, salbutamol tablets, albuterol tablets

Type: compound

Route/form: oral

Status: approved_drug_off_label_performance_discussion

Evidence level: human RCT

Best data tier: human controlled/review; exact-use indirect

Support scope: human, review/regulatory

Source types: human_rct, human_rct_negative, review

Linked sources: 4

Broad outcomes: Cardiovascular / lipids / blood pressure, Fat loss / metabolic health, Muscle growth / performance / recovery, PEDs / AAS / thermogenics, Safety / regulatory

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• beta-2 adrenergic receptor agonism
• bronchodilation
• ergogenic effect

Optimization domains

• exercise performance
• fat loss
• doping
• cardiovascular risk

Research basis

• Human oral salbutamol trials report ergogenic or metabolic effects under some protocols, including muscle strength/endurance and exercise-endurance/metabolism signals.
• It is a coherent non-androgenic performance lead because oral beta-2 agonism can produce systemic skeletal-muscle effects distinct from inhaled asthma dosing.
• The mixed human evidence makes it a protocol-dependent signal entry rather than a blanket performance enhancer.

Limits, risks, and missing evidence

• A later acute oral salbutamol study in recreational male athletes found no relevant ergogenic effect on muscle contractility/fatigability, so the signal is inconsistent.
• Performance use raises anti-doping, tachycardia, tremor, anxiety, potassium, and cardiac-risk issues.
• Inhaled therapeutic asthma use and oral performance use should not be collapsed.

Risk flags

• prescription drug
• off label performance context
• stimulant cardiovascular risk
• hypokalemia
• doping

Linked papers, labels, and reviews

1. Effect of salbutamol on muscle strength and endurance performance in nonasthmatic men
   human_rct / pubmed_salbutamol_strength_endurance_2000
   Double-blind placebo-controlled study in nonasthmatic men; direct source for oral salbutamol ergogenic discussion.
2. Effects of salbutamol on the contractile properties of human skeletal muscle before and after fatigue
   human_rct_negative / pubmed_salbutamol_contractile_properties_2011
   Randomized double-blind acute oral salbutamol study in nonasthmatic recreational male athletes; found no relevant ergogenic effect on muscle contractility/fatigability.
3. Do inhaled beta-2 agonists have an ergogenic potential in non-asthmatic competitive athletes?
   review / pubmed_beta2_agonists_ergogenic_2007
   Review contrasting mostly non-ergogenic inhaled beta-2 agonists with oral salbutamol signals.
4. Effects of short-term oral salbutamol administration on exercise endurance and metabolism
   human_rct / pubmed_salbutamol_endurance_metabolism_2000
   Oral salbutamol exercise-endurance/metabolism trial; complements strength/endurance trial and reinforces route-specific beta2-agonist discussion.